Table 1 Patient characteristics of 184 patients.
All patients (n = 184) | Paroxysmal AF (n = 94) | Persistent AF (n = 90) | |
|---|---|---|---|
Age (years) | 68.7 ± 8.9 | 70.1 ± 7.6 | 67.2 ± 9.9* |
Sex | |||
Male, n (%) | 133 (72) | 60 (64) | 73 (81)** |
Female, n (%) | 51 (27) | 34 (36) | 17 (19)** |
BMI (kg/m2) | 24.5 ± 3.1 | 24.0 ± 2.9 | 24.9 ± 3.1* |
CHADS2 score | 1.6 ± 1.2 | 1.76 ± 1.14 | 1.50 ± 1.16 |
HT, n (%) | 113 (61) | 66 (70) | 47 (52)* |
DM, n (%) | 41 (22) | 20 (21) | 21 (23) |
HF, n (%) | 36 (20) | 11 (12) | 25 (28)** |
Medication | |||
ACEI or ARB, n (%) | 77 (42) | 39 (41) | 38 (42) |
β-blocker, n (%) | 85 (46) | 41 (44) | 44 (49) |
Statin, n (%) | 64 (35) | 34 (36) | 30 (33) |
Amiodarone, n (%) | 52 (28) | 16 (17) | 36 (40)** |
Labo data | |||
Hb (g/dl) | 13.8 ± 1.7 | 13.4 ± 1.5 | 14.2 ± 1.89** |
Cr (mg/dl) | 1.1 ± 1.2 | 1.14 ± 1.44 | 1.04 ± 0.82 |
eGFR (ml/min/1.73 m2) | 61.7 ± 19.1 | 62.9 ± 21.0 | 60.6 ± 16.7 |
pro BNP (pg/ml) | 918.8 ± 2917.0 | 414.8 ± 689.7 | 1434.3 ± 4024.9* |
HbA1c (%) | 5.9 ± 0.6 | 5.9 ± 0.6 | 6.0 ± 0.6 |
LDL-C (mg/dl) | 106.5 ± 31.3 | 109.1 ± 29.1 | 103.8 ± 33.2 |
HDL-C (mg/dl) | 57.3 ± 14.4 | 58.1 ± 14.1 | 56.4 ± 14.7 |
TG (mg/dl) | 116.3 ± 68.9 | 113.3 ± 65.2 | 119.5 ± 72.5 |
Echo data | |||
LAD (mm) | 40.9 ± 5.6 | 38.8 ± 5.7 | 43.1 ± 4.6** |
LVDd (mm) | 48.5 ± 5.5 | 47.7 ± 5.3 | 49.3 ± 5.6 |
LVDs (mm) | 31.9 ± 6.3 | 30.7 ± 6.1 | 33.3 ± 6.3** |
LVEF (%) | 62.7 ± 11.6 | 65.1 ± 10.5 | 60.2 ± 12.0** |
E/e′ | 12.7 ± 5.3 | 12.9 ± 5.4 | 12.5 ± 5.1 |